

CITATION REPORT

List of articles citing

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients

DOI: 10.1001/archneurol.2010.65
Archives of Neurology, 2010, 67, 589-95.

Source: <https://exaly.com/paper-pdf/48771053/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1119	Parkinson disease: an update. 2004 , 10, 185-94		18
1118	DRUG NEWS. 2010 , 40, 18		1
1117	Caring for patients with Parkinson disease. 2010 , 40, 58-64		1
1116	Impulsive choice and response in dopamine agonist-related impulse control behaviors. 2010 , 207, 645-59		154
1115	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. 2010 , 68, 963-8		105
1114	Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. 2010 , 75, 1711-6		171
1113	Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery. 2010 , 133, e155; author reply e156		13
1112	Role of pramipexole in the management of Parkinson's disease. 2010 , 24, 829-41		39
1111	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. 2010 , 5, 851-871		8
1110	Cuidar de los pacientes con enfermedad de Parkinson Su funci3n. 2010 , 28, 22-28		
1109	Imaging cognitive and behavioral symptoms in Parkinson's disease. 2010 , 10, 1827-38		15
1108	Apathie et addictions comportementales dans la maladie de Parkinson: l'endroit et l'envers d'une m4me m4daille?. 2011 , 2, 123-130		4
1107	Neurologic manifestations of chronic methamphetamine abuse. 2011 , 29, 641-55		69
1106	Dopamine agonists and risk: impulse control disorders in Parkinson's disease. 2011 , 134, 1438-46		162
1105	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. 2011 , 134, 969-78		245
1104	Trastornos neurol3gicos: repasemos nuestros conocimientos. 2011 , 29, 56-59		
1103	Impulse control disorders and punning in Parkinson's disease: The need for a structured interview. 2011 , 26, 166-172		1

1102	Impulsive and compulsive behaviors in Parkinson's disease: a one-year follow-up study. 2011 , 310, 197-201	28
1101	Sexual problems in Parkinson's disease: the multidimensional nature of the problem and of the intervention. 2011 , 310, 139-43	23
1100	Impulsivity and Parkinson's disease: more than just disinhibition. 2011 , 310, 202-7	31
1099	The role of impulse control disorders in Tourette syndrome: an exploratory study. 2011 , 310, 276-8	63
1098	Neural reward processing under dopamine agonists: imaging. 2011 , 310, 36-9	9
1097	Dopaminergic dysregulation syndrome in Parkinson's disease. 2011 , 310, 271-5	31
1096	Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. 2011 , 310, 183-8	38
1095	Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. 2011 , 310, 64-9	57
1094	Cognitive and psychiatric disturbances in Parkinson's disease. 2011 , 7, 123-142	5
1093	Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice. 2011 , 27, 1899-905	11
1092	Impulse control disorders and dopaminergic treatments in Parkinson's disease. 2011 , 167, 827-32	6
1091	Impulse control disorders in Parkinson's disease: clinical characteristics and implications. 2011 , 1, 133-147	28
1090	Cognitive enhancement by drugs in health and disease. 2011 , 15, 28-36	180
1089	Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. 2011 , 32, 148-57	90
1088	Clinical predictors of frequent patient telephone calls in Parkinson's disease. 2011 , 17, 95-9	16
1087	Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. 2011 , 17, 153-5	52
1086	Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. 2011 , 17, 260-4	66
1085	Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. 2011 , 17, 295-6	9

1084	Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. 2011 , 17, 413-7	97
1083	Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist. 2011 , 17, 635-7	26
1082	Impulsive-compulsive behaviors are common in Asian Parkinson's disease patients: assessment using the QUIP. 2011 , 17, 761-4	37
1081	Neuroscience of behavioral and pharmacological treatments for addictions. 2011 , 69, 695-712	162
1080	Dopamine-induced nonmotor symptoms of Parkinson's disease. 2011 , 2011, 485063	27
1079	Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. 2011 , 2011, 572743	80
1078	Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. 2011 , 2011, 658415	33
1077	Available and emerging treatments for Parkinson's disease: a review. 2011 , 5, 241-54	27
1076	Modulation of habit formation by levodopa in Parkinson's disease. 2011 , 6, e27695	4
1075	Impulse control disorders in Parkinson's disease: recent advances. 2011 , 24, 324-30	137
1074	Current world literature. 2011 , 24, 409-13	
1073	Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. 2011 , 34, 179-81	53
1072	Pharmacological evaluation of the adequacy of marble burying as an animal model of compulsion and/or anxiety. 2011 , 22, 711-3	30
1071	Pramipexole and its extended release formulation for Parkinson's disease. 2011 , 3, 169-78	2
1070	Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. 2011 , 106, 283-93	66
1069	Behavioral and personality features in patients with lateralized Parkinson's disease. 2011 , 18, 772-7	9
1068	Priorities in Parkinson's disease research. 2011 , 10, 377-93	317
1067	Impulse control disorders and punding in Parkinson's disease: the need for a structured interview. 2011 , 26, 166-72	13

1066	Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. 2011 , 104, 168-72	50
1065	Strategies for Parkinson's disease care: prevention and management of motor fluctuations. 2011 , 1, 415-430	
1064	Pathological gambling in Parkinson's disease: disease related or drug related?. 2011 , 11, 809-14	7
1063	Pramipexole for the treatment of early Parkinson's disease. 2011 , 11, 925-35	16
1062	Pathological gambling in Parkinson's disease--a review of the literature. 2011 , 26, 1976-84	38
1061	Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. 2011 , 216, 289-99	62
1060	Drug-induced impulse control disorders in Parkinson's disease. 2011 , 258, S323-7	13
1059	Phenotype analysis in patients with early onset Parkinson's disease with and without parkin mutations. 2011 , 258, 2260-7	21
1058	Drug-Induced Impulse Control Disorders: A Prospectus for Neuroethical Analysis. 2011 , 4, 91-102	15
1057	Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. 2011 , 11, 117	85
1056	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. 2011 , 26, 464-8	115
1055	A failure to communicate: preliminary evidence for cortico-striatal dysconnection with pathological gambling in Parkinson's disease. 2011 , 26, 193-4	
1054	Parkinson's disease: the quintessential neuropsychiatric disorder. 2011 , 26, 1022-31	277
1053	Milestones in Parkinson's disease therapeutics. 2011 , 26, 1072-82	132
1052	Intertemporal choice in Parkinson's disease. 2011 , 26, 2004-10	49
1051	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. 2011 , 26 Suppl 3, S2-41	397
1050	Hypersexuality and pathological gambling in Parkinson's disease: A cross-sectional case-control study. 2011 , 26, 2127-30	19
1049	Impulse control disorders in Parkinson disease: a multicenter case-control study. 2011 , 69, 986-96	296

1048	Evaluation and management of the non-motor features of Parkinson's disease. 2011 , 2, 69-85	14
1047	Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. 2011 , 2011, 928523	7
1046	Sleep-related eating disorder in two patients with early-onset Parkinson's disease. 2011 , 66, 106-9	12
1045	Behavioural disorders, disability and quality of life in Parkinson's disease. 2011 , 40, 614-21	66
1044	Nonmotor disorders and their correlation with dopamine: can they be treated by currently available methods?. 2011 , 17, S9-17	5
1043	Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease. 2011 , 336, 423-30	32
1042	Nonmotor problems in Parkinson disease. 2011 , 183-196	
1041	Medical treatment of Parkinson disease. 2011 , 119-156	
1040	Parkinson's: treating the symptoms. 2011 , 20, 852, 854-7	2
1039	Nonmotor disturbances in Parkinson's disease. 2011 , 8, 95-108	38
1038	Movement disorders in 2010: Parkinson disease-symptoms and treatments. 2011 , 7, 70-2	16
1037	The risky business of dopamine agonists in Parkinson disease and impulse control disorders. 2011 , 125, 492-500	80
1036	Management of sexual dysfunction in Parkinson's disease. 2011 , 4, 375-83	77
1035	Pharmacologic safety concerns in Parkinson's disease: facts and insights. 2011 , 121 Suppl 2, 45-52	17
1034	Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. 2011 , 121, 472-6	5
1033	Diagnosis and initiation of treatment in Parkinson's disease. 2011 , 121 Suppl 2, 27-36	13
1032	Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. 2012 , 2, 267-274	39
1031	Parkinson's disease: treatment and non-motor features. 2012 , 22, 243-260	3

1030	Pathological gambling: prevalence, diagnosis, comorbidity, and intervention in Germany. 2012 , 109, 173-9	20
1029	Therapies in Parkinson's disease. 2012 , 25, 433-47	141
1028	Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. 2012 , 35, 261-5	64
1027	Psychiatric syndromes in Parkinson's disease. 2012 , 25, 468-72	44
1026	Nonmotor manifestations in Parkinson disease. 2012 , 18, 1-16	49
1025	Comparison of personality characteristics in Parkinson disease patients with and without impulse control disorders and in healthy volunteers. 2012 , 25, 25-33	12
1024	Relations among delay discounting, addictions, and money mismanagement: implications and future directions. 2012 , 38, 30-42	38
1023	Parallel appearance of compulsive behaviors and artistic creativity in Parkinson's disease. 2012 , 4, 77-83	17
1022	Impulse control disorders in Parkinson's disease: background and update on prevention and management. 2012 , 2, 389-400	9
1021	Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls. 2012 , 37, 1397-408	57
1020	In for a penny, in for a pound: methylphenidate reduces the inhibitory effect of high stakes on persistent risky choice. 2012 , 32, 13032-8	25
1019	Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?. 2012 , 5, 23-41	20
1018	Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease. 2012 , 57, 217-20	3
1017	The epidemiology and clinical manifestations of dysexecutive syndrome in Parkinson's disease. 2012 , 3, 159	24
1016	The temptation of suicide: striatal gray matter, discounting of delayed rewards, and suicide attempts in late-life depression. 2012 , 42, 1203-15	137
1015	Dissecting the effects of disease and treatment on impulsivity in Parkinson's disease. 2012 , 18, 942-51	13
1014	Deep brain stimulation and behavioural changes: is comedication the most important factor?. 2012 , 9, 18-24	10
1013	Finasteride attenuates pathological gambling in patients with Parkinson disease. 2012 , 32, 424-5	35

1012	[Pathological gambling in patients with Parkinson disease]. 2012 , 37, 189-202	2
1011	Sexual Behavior. 2012 ,	
1010	Canadian Guidelines on Parkinson's Disease. 2012 , 39, S1-30	81
1009	Neuropsychiatric effects of Parkinson's disease treatment. 2012 , 31, 198-202	11
1008	Drug treatments for the neuropsychiatric complications of Parkinson's disease. 2012 , 12, 1439-49	20
1007	Impulse control disorders in Parkinson's disease. 2012 , 18 Suppl 1, S80-4	54
1006	Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. 2012 , 259, 2269-77	35
1005	Long-term outcomes of surgical therapies for Parkinson's disease. 2012 , 27, 1718-28	97
1004	[Repetitive impulse-associated behavioral disorders in Parkinson's disease]. 2012 , 83, 1582-9	1
1003	A short scale for evaluation of neuropsychiatric disorders in Parkinson's disease: first psychometric approach. 2012 , 259, 2299-308	24
1002	Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. 2012 , 259, 2752-4	11
1001	[Imaging non motor signs in Parkinson's disease]. 2012 , 168, 576-84	
1000	Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. 2012 , 62, 115-24	136
999	Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. 2012 , 18, 76-8	53
998	Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. 2012 , 18, 10-6	33
997	Impulse control disorders and depression in Finnish patients with Parkinson's disease. 2012 , 18, 155-60	84
996	Apathy and impulse control disorders in Parkinson's disease: a direct comparison. 2012 , 18, 198-203	43
995	Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. 2012 , 18, 207-9	37

994	Non-motor symptoms of Parkinson's disease in China: a review of the literature. 2012 , 18, 446-52	32
993	Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. 2012 , 135, 1463-77	242
992	Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls. 2012 , 233, 15-23	31
991	Drug therapy in patients with Parkinson's disease. 2012 , 1, 10	66
990	Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. 2012 , 167, 327-35	26
989	How neurodegeneration, dopamine and maladaptive behavioral learning interact to produce impulse control disorders in Parkinson's disease. 2012 , 2, 195-199	3
988	Impulsivity, impulse control disorders, and subthalamic stimulation in Parkinson's disease. 2012 , 2, 205-209	4
987	Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. 2012 , 59, 3339-46	46
986	The motor system and its disorders. 2012 , 61, 464-77	47
985	Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. 2012 , 18, 1079-83	30
984	Functional imaging of non-motor signs in Parkinson's disease. 2012 , 315, 9-14	8
983	Parkinson's disease. 2012 , 40, 529-535	18
982	[Impulse control disorders in Parkinson's disease: A cohort of 35 patients]. 2012 , 168, 143-51	6
981	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [¹¹ C] FLB-457 and PET study. 2012 , 48, 519-25	101
980	Addictive behaviors and Parkinson's disease. 2012 , 168, 624-33	21
979	Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. 2012 , 122, 145-53	32
978	Drug Repositioning Efforts by Nonprofit Foundations. 2012 , 389-431	
977	Pathological Gambling: Neuropsychopharmacology and Treatment. 2012 , 1,	25

976	Frontostriatal cognitive staging in Parkinson's disease. 2012 , 2012, 561046	24
975	Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. 2012 , 2012, 198316	59
974	Dopamine agonists and pathologic behaviors. 2012 , 2012, 603631	21
973	Raising awareness of impulsive and compulsive behaviour in Parkinson's. 2012 , 8, 162-162	
972	Decision making, impulsivity, and addictions: do Parkinson's disease patients jump to conclusions?. 2012 , 27, 1137-45	68
971	Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. 2012 , 24, 1709-24	56
970	Impulse control disorders in Parkinson's disease: a psychosocial perspective. 2012 , 19, 338-46	18
969	Do Parkinson's disease patients disclose their adverse events spontaneously?. 2012 , 68, 857-65	16
968	Personality traits in patients with Parkinson's disease: assessment and clinical implications. 2012 , 259, 1029-38	59
967	Addiction as aberrant learning-evidence from Parkinson's disease. 2012 , 107, 248-50	3
966	Stimulating debate in the field of addiction. 2012 , 107, 253	1
965	Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. 2012 , 11, 429-42	277
964	Are there ethnic differences in impulsive/compulsive behaviors in Parkinson's disease?. 2012 , 19, 494-500	23
963	Perceptions of cause and control of impulse control behaviours in people with Parkinson's disease. 2012 , 17, 522-35	9
962	Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. 2012 , 27, 242-7	202
961	Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. 2012 , 27, 778-82	37
960	Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. 2012 , 219, 123-35	19
959	Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. 2012 , 219, 469-90	313

958	Effects of pramipexole on the processing of rewarding and aversive taste stimuli. 2013 , 228, 283-90	12
957	Risky choices link the subthalamic nucleus with pathological gambling in Parkinson's disease. 2013 , 28, 1617-9	4
956	Evidence-based advances in the treatment of motor features of Parkinson's disease. 2013 , 3, 331-341	
955	Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. 2013 , 260, 429-37	20
954	Disordered gambling: a behavioral addiction. 2013 , 23, 655-9	90
953	Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson's disease versus behavioural variant frontotemporal dementia. 2013 , 49, 1833-43	56
952	Reinforcing properties of Pramipexole in normal and parkinsonian rats. 2013 , 49, 79-86	26
951	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. 2013 , 136, 400-11	151
950	Sex, drugs and Parkinson's disease. 2013 , 136, 371-3	4
949	Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area. 2013 , 252, 24-31	26
948	Depression in Parkinson's disease: identification and management. 2013 , 33, 972-83	29
947	Psychiatric considerations in deep brain stimulation for Parkinson's disease. 2013 , 116, 147-54	11
946	Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials. 2013 , 19, 930-6	22
945	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. 2013 , 24, 267-78	121
944	Clinical outcome of deep brain stimulation for Parkinson's disease. 2013 , 116, 107-28	58
943	Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. 2013 , 13, 1329-42	5
942	Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. 2013 , 110, 63-73	38
941	Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. 2013 , 20, 964-9	34

940	Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. 2013 , 3, 101-13	66
939	The functional anatomy of impulse control disorders. 2013 , 13, 386	47
938	Executive dysfunction in Parkinson's disease: a review. 2013 , 7, 193-224	302
937	Advanced Parkinson's disease: Clinical characteristics and treatment. Part II. 2013 , 28, 558-583	3
936	De ziekte van Parkinson: van geremde motoriek tot ontremde impulsen. 2013 , 17, 106-112	
935	Anticipating possible policy uses of addiction neuroscience research. 2013 , 20, 249-257	4
934	Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. 2013 , 84, 1113-8	119
933	Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability. 2013 , 19, 37-42	25
932	A common optimization principle for motor execution in healthy subjects and parkinsonian patients. 2013 , 33, 665-77	47
931	Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. 2013 , 19, 483-4	22
930	Advanced Parkinson's disease: clinical characteristics and treatment. Part II. 2013 , 28, 558-83	31
929	Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson's Disease in the United States. 2013 , 19, 202-6	29
928	Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. 2013 , 84, 868-74	83
927	Diagnosis and treatment of impulse control disorders in patients with movement disorders. 2013 , 6, 175-88	26
926	Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?. 2013 , 28, 1915-9	26
925	Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. 2013 , 19, 269-70	11
924	Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. 2013 , 19, 698-700	38
923	Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude. 2013 , 51, 2679-89	8

922	Screening hypersexuality in Parkinson's disease in everyday practice. 2013 , 19, 242-6	19
921	German versions of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP) and the QUIP-Rating Scale. 2013 , 3, 61-62	
920	La kleptomanie : un trouble du contrôle des impulsions méconnu. 2013 , 4, 187-190	
919	Extended-release carbidopa-levodopa in Parkinson's disease. 2013 , 12, 325-6	7
918	Impulse control and related disorders in Parkinson's disease. 2013 , 11, 63-71	68
917	Prospective cohort study of impulse control disorders in Parkinson's disease. 2013 , 28, 327-33	105
916	Pathological gambling in Parkinson's disease. A comprehensive review. 2013 , 19, 645-53	51
915	The subthalamic nucleus is involved in successful inhibition in the stop-signal task: a local field potential study in Parkinson's disease. 2013 , 239, 1-12	114
914	Genetics of impulse control disorders in Parkinson's disease. 2013 , 120, 665-71	33
913	Imaging impulse control disorders in Parkinson's disease and their relationship to addiction. 2013 , 120, 659-64	18
912	Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. 2013 , 12, 346-56	149
911	Neurologic manifestations of chronic methamphetamine abuse. 2013 , 36, 261-75	70
910	The effects of clinical motor variables and medication dosage on working memory in Parkinson's disease. 2013 , 82, 137-45	19
909	Involuntary Movement Disorders. 2013 , 397-453	
908	Dopamine agonist withdrawal syndrome: implications for patient care. 2013 , 30, 587-92	80
907	Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease. 2013 , 331, 76-80	21
906	Biomarkers in Parkinson's disease (recent update). 2013 , 63, 201-29	147
905	Initial treatment of Parkinson's disease: an update. 2013 , 15, 377-84	5

904	Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease: BRAZIL. 2013 , 3, 479-480	
903	Medications and Cognition in Older Adults. 2013 , 89-107	
902	New horizons in the pathogenesis, assessment and management of movement disorders. 2013 , 42, 2-10	5
901	Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease. 2013 , 136, 1192-203	36
900	Managing impulse control behaviours in Parkinson's disease: practical guidelines. 2013 , 74, 160-6	13
899	Management of cognitive and behavioral aspects of Parkinson's disease. 2013 , 79-98	
898	Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. 2013 , 80, 792-9	132
897	Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease. 2013 , 127, 245-55	33
896	Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. 2013 , 80, 176-80	150
895	Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. 2013 , 45, 547-55	18
894	A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. 2013 , 33, 691-4	59
893	Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. 2013 , 28, 2007-10	45
892	Management of non-motor symptoms of Parkinson's disease. 2013 , 61-78	
891	Imbalance in the sensitivity to different types of rewards in pathological gambling. 2013 , 136, 2527-38	110
890	Affective disorders in Parkinson's disease. 2013 , 26, 339-44	8
889	Impulsivity and apathy in Parkinson's disease. 2013 , 7, 255-83	54
888	Dopaminergic influences on executive function and impulsive behaviour in impulse control disorders in Parkinson's disease. 2013 , 7, 306-25	34
887	Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice. 2013 , 99, 290-317	4

886	Physiotherapy management of Parkinson's and of older people. 2013 , 539-559	
885	The role of physiotherapy in the rehabilitation of people with movement disorders. 55-68	1
884	The role of neuropsychology in the rehabilitation of people with movement disorders. 94-109	
883	Overview of Parkinson's disease: epidemiology, diagnosis, course, medical and surgical management. 1-13	
882	Parkinson's disease: pathology, anatomy, and behavior. 14-24	
881	Cognitive assessment in Parkinson's disease. 53-64	
880	Imaging and behavior in Parkinson's disease: structural imaging. 73-88	
879	Depression. 109-118	
878	Impulse control disorders and related behaviors. 140-152	2
877	Management. 211-229	
876	Surgical treatment and behavior. 230-243	
875	The genetics of behavior and cognition in Parkinson's disease. 25-39	
874	Initial and disease-modifying strategies in Parkinson's disease. 2013 , 23-41	
873	Neuropsychiatrische Störungen beachten. 2013 , 14, 42-48	2
872	Impulse control disorders and related behaviors in Indian patients with Parkinson's disease. 2013 , 28, 1901-2	18
871	Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome. 2013 , 36, 1501-7	46
870	Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease. 2013 , 4, 90	15
869	Dopaminergic and clinical correlates of pathological gambling in Parkinson's disease: a case report. 2013 , 7, 95	9

868	Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers. 2013 , 7, 138	22
867	How central is dopamine to pathological gambling or gambling disorder?. 2013 , 7, 206	83
866	Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD. 2013 , 4, 90	17
865	Reformulating psychological difficulties in people with Parkinson's disease: the potential of a social relational approach to disablism. 2013 , 2013, 608562	27
864	Design and customization of telemedicine systems. 2013 , 2013, 618025	16
863	Neural correlates of sexual cue reactivity in individuals with and without compulsive sexual behaviours. 2014 , 9, e102419	249
862	Trait impulsivity is associated with the risk of falls in Parkinson's disease. 2014 , 9, e91190	19
861	Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. 2014 , 2014, 260485	5
860	Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. 2014 , 10, 1093-101	18
859	Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease. 2014 , 6, 180	27
858	Impulsive and compulsive behaviors in Parkinson's disease. 2014 , 6, 318	23
857	The role of dopamine in risk taking: a specific look at Parkinson's disease and gambling. 2014 , 8, 196	31
856	A new approach to assess gambling-like behavior in laboratory rats: using intracranial self-stimulation as a positive reinforcer. 2014 , 8, 215	7
855	Dopamine and the biology of creativity: lessons from Parkinson's disease. 2014 , 5, 55	33
854	Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology update. 2014 , 7, 67-76	9
853	Perceptual decision-making in patients with Parkinson's disease. 2014 , 28, 1149-54	17
852	Apathy in Parkinson's disease: neurophysiological evidence of impaired incentive processing. 2014 , 34, 5918-26	46
851	Dopamine D2-like receptor activation wipes out preferential consolidation of high over low reward memories during human sleep. 2014 , 26, 2310-20	66

850	Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review. 2014 , 2014, 728038	10
849	Dopaminergic influences on emotional decision making in euthymic bipolar patients. 2014 , 39, 274-82	22
848	Lesson of the month (1): cabergoline - 'i eat funny on that'. 2014 , 14, 205-7	4
847	Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP). 2015 , 18, 49-59	27
846	Resolution of Othello Syndrome After Subthalamic Nucleus Deep Brain Stimulation in 3 Patients with Parkinson's Disease. 2014 , 1, 357-360	3
845	Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. 2014 , 1329, 45-66	23
844	Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. 2014 , 83, 826-33	59
843	Treatment of early Parkinson's disease. 2014 , 27, 442-9	28
842	Premotor and nonmotor features of Parkinson's disease. 2014 , 27, 434-41	195
841	Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. 2014 , 85, 840-4	156
840	The contribution of apathy and increased learning trials to risky decision-making in Parkinson's disease. 2014 , 29, 100-9	17
839	Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma. 2014 , 85, 471	4
838	Course of psychiatric symptoms and global cognition in early Parkinson disease. 2014 , 83, 1096-103	82
837	Mechanisms of body weight fluctuations in Parkinson's disease. 2014 , 5, 84	61
836	Gene therapy for Parkinson's disease: a step closer?. 2014 , 383, 1107-9	15
835	Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. 2014 , 17, 150-6	40
834	Developments in neuroimaging: positron emission tomography. 2014 , 20 Suppl 1, S180-3	8
833	Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. 2014 , 13, 287-305	214

832	Dopaminergic agonists in Parkinson's disease. 2014 , 29, 230-241	5
831	Psychiatric issues in cognitive impairment. 2014 , 29, 651-62	37
830	Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. 2014 , 85, 148-52	60
829	Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. 2014 , 29, 904-11	74
828	Treatment of Gambling Disorders. 2014 , 1, 189-203	81
827	Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. 2014 , 11, 78-91	46
826	Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. 2014 , 21, 63-6	59
825	Dopamine receptor agonists for Parkinson's disease. 2014 , 23, 387-410	31
824	Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?. 2014 , 38, 60-71	71
823	Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study. 2014 , 215, 448-52	71
822	Behavioral disorders in Parkinson's disease: the role of dopamine. 2014 , 20 Suppl 1, S10-2	19
821	Disordered gambling: the evolving concept of behavioral addiction. 2014 , 1327, 46-61	99
820	Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling. 2014 , 20, 1209-14	30
819	Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: a case series. 2014 , 20, 1290-2	10
818	Initiating dopaminergic treatment in Parkinson's disease. 2014 , 384, 1164-6	13
817	Impulse control and repetitive behaviors in Parkinson's disease - are there differences in the relation to dopamine agonist treatment?. 2014 , 345, 252-3	1
816	The neural bases of cognitive processes in gambling disorder. 2014 , 18, 429-38	64
815	Parkinson disease: Can a new trial end controversy over when to use levodopa?. 2014 , 10, 488-9	1

814	Inhibition of apomorphine-induced conditioned place preference in rats co-injected with buspirone: relationship with serotonin and dopamine in the striatum. 2014 , 1586, 73-82	13
813	Brain alterations in paedophilia: a critical review. 2014 , 122, 1-23	67
812	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. 2014 , 261, 936-42	32
811	The expanding universe of disorders of the basal ganglia. 2014 , 384, 523-31	117
810	Impulscontrolestoornissen bij behandelde Parkinsonpatiënten: diagnostische en therapeutische dilemma's. 2014 , 2, 12-20	
809	Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. 2014 , 20, 22-6	70
808	Hypomania and mania related to dopamine replacement therapy in Parkinson's disease. 2014 , 20, 421-7	26
807	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. 2014 , 384, 532-44	104
806	Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. 2014 , 85, 311-8	42
805	Gender differences in non-motor symptoms in early Parkinson's disease: a 2-years follow-up study on previously untreated patients. 2014 , 20, 850-4	43
804	When benefitting a patient increases the risk for harm for third persons - the case of treating pedophilic Parkinsonian patients with deep brain stimulation. 2014 , 37, 295-303	15
803	Non-substance addictive behaviors in the context of DSM-5. 2014 , 39, 1-2	141
802	Targeting impulsivity in Parkinson's disease using atomoxetine. 2014 , 137, 1986-97	93
801	Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. 2014 , 137, 1145-55	77
800	Impulsive and compulsive behaviors in Parkinson's disease. 2014 , 10, 553-80	43
799	Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. 2014 , 85, 23-30	35
798	Problematic Internet use in Parkinson's disease. 2014 , 20, 482-7	12
797	Impulse control and related disorders in Mexican Parkinson's disease patients. 2014 , 20, 907-10	32

796	Greater striatal responses to medication in Parkinson's disease are associated with better task-switching but worse reward performance. 2014 , 62, 390-7	47
795	Dopaminergic agonists in Parkinson's disease. 2014 , 29, 230-41	20
794	Do Parkinson's Disease Patients Have Deficits in Sequential Sampling Tasks?. 2014 , 1, 325-328	1
793	Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration's Adverse Event database. 2014 , 3, 21-6	8
792	Optimal target localization for subthalamic stimulation in patients with Parkinson disease. 2014 , 82, 1352-61	108
791	Compulsive behaviors related to rasagiline: a case report. 2014 , 34, 529-30	3
790	Non-motor symptoms: the core of multi-morbid Parkinson's disease. 2014 , 75, 18-24	32
789	Intertemporal choice in Parkinson's disease and restless legs syndrome. 2015 , 21, 1330-5	19
788	Translational Models of Gambling-Related Decision-Making. 2016 , 28, 93-120	24
787	Betting on DBS: Effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson's disease. 2015 , 29, 622-631	22
786	Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors. 2015 , 5, 625-36	45
785	Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. 2015 , 30, 393-415	18
784	Hypersexuality in Parkinson's Disease: Systematic Review and Report of 7 New Cases. 2015 , 2, 116-126	20
783	Clozapine Treatment for Impulse Control Disorders in Parkinson's Disease Patients: A Case Series. 2015 , 2, 283-285	2
782	How to optimize the treatment of early stage Parkinson's disease. 2015 , 4, 4	19
781	Assessing patient outcome and troubleshooting deep brain stimulation. 138-181	
780	[Gambling addiction: insights from neuroscience and neuroimaging]. 2015 , 31, 784-91	0
779	Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease. 2015 , 30, 736-9	19

778	Parkinson's Disease, Religion, and Spirituality. 2015 , 2, 341-346	6
777	Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders. 2015 , 30, 696-704	28
776	Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years' Follow-up. 2015 , 38, 132-4	39
775	Implications of functional neurosurgery and deep-brain stimulation for free will and decision-making. 191-204	
774	Are addicted individuals responsible for their behaviour?. 146-167	
773	Whole-brain diffusion-tensor changes in parkinsonian patients with impulse control disorders. 2015 , 11, 42-7	26
772	Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson's Disease. 2015 , 9, 317	14
771	Chronic pramipexole treatment increases tolerance for sucrose in normal and ventral tegmental lesioned rats. 2014 , 8, 437	7
770	Neuroimaging studies of striatum in cognition part II: Parkinson's disease. 2015 , 9, 138	29
769	Why do Parkinson's Disease Patients Sometimes Make Wrong Decisions?. 2015 , 5, 637-42	7
768	Perceived Cost and Intrinsic Motor Variability Modulate the Speed-Accuracy Trade-Off. 2015 , 10, e0139988	12
767	Piribedil and pathological gambling in six parkinsonian patients. 2015 , 73, 115-8	9
766	Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease. 2015 , 2015, 970862	4
765	Sexuality in patients with Parkinson's disease, Alzheimer's disease, and other dementias. 2015 , 130, 297-323	34
764	Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?. 2015 , 370,	51
763	Unmasking nonmotor symptoms of Parkinson disease. 2015 , 45, 26-32; quiz 32-3	2
762	Angiotensin II type 2 receptor signaling affects dopamine levels in the brain and prevents binge eating disorder. 2015 , 16, 749-57	6
761	Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. 2015 , 262, 2653-61	30

760	EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. 2015 , 30, 510-6	161
759	Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease. 2015 , 25, 69-76	28
758	A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson's disease. 2015 , 225, 402-6	9
757	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. 2015 , 30, 150-9	71
756	Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. 2015 , 69, 183-9	90
755	[Hypersexuality in Parkinson's disease. Advantage of the presence of the entourage for medical assessment]. 2015 , 44, e51-8	3
754	Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. 2015 , 30, 141-9	68
753	Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease?. 2015 , 47, 29-45	9
752	The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder. 2015 , 27, 205-8	14
751	Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments. 2015 , 22, 603-9	32
750	New and emerging treatments for Parkinson disease. 2015 , 202, 283-4	5
749	Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. 2015 , 230, 44-9	7
748	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. 2015 , 132, 96-168	282
747	Improving response inhibition systems in frontotemporal dementia with citalopram. 2015 , 138, 1961-75	49
746	Functional Studies of Parkinson's Disease. 2015 , 713-720	
745	Irrational beliefs, biases and gambling: exploring the role of animal models in elucidating vulnerabilities for the development of pathological gambling. 2015 , 279, 259-73	36
744	Single versus multiple impulse control disorders in Parkinson's disease: an ^{11}C -raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. 2015 , 262, 1504-14	35
743	Paraphilias and paraphilic disorders in Parkinson's disease: A systematic review of the literature. 2015 , 30, 604-13	27

742	Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease. 2015 , 10, 191-201	
741	Sensation-seeking: Dopaminergic modulation and risk for psychopathology. 2015 , 288, 79-93	71
740	Neuropsychological findings in a case of punding before and after cessation of pramipexole. 2015 , 29, 166-78	4
739	Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease. 2015 , 56, 1036-41	21
738	Pet killing as a manifestation of impulse control disorder secondary to pramipexol. 2015 , 38, 55-6	7
737	Gambling disorder and other behavioral addictions: recognition and treatment. 2015 , 23, 134-46	105
736	Cognitive Decline and Dementia in Parkinson's Disease. 2015 , 113-125	
735	Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?. 2015 , 30, 632-7	14
734	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. 2015 , 30, 919-27	179
733	International validation of a behavioral scale in Parkinson's disease without dementia. 2015 , 30, 705-13	67
732	Impulse control dysfunction and dopamine agonist withdrawal syndrome in Genetic Parkinson's: A case report. 2015 , 5, 57-58	3
731	Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches. 2015 , 56, 294-314	31
730	The agony of the agonists: a review of impulsivity and withdrawal syndromes in Parkinson's disease treatment. 2015 , 10, 357-367	1
729	Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?. 2015 , 82, 561-573	17
728	Dopamine enhances willingness to exert effort for reward in Parkinson's disease. 2015 , 69, 40-6	154
727	Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions. 2015 , 75, 577-87	26
726	Modulation of Saccade Vigor during Value-Based Decision Making. 2015 , 35, 15369-78	60
725	Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. 2015 , 49, 157-70	22

724	Behavioral effects of levodopa. 2015 , 30, 90-102	52
723	Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. 2015 , 129, 19-25	34
722	Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships. 2015 , 25, 17-25	23
721	Clinical spectrum of impulse control disorders in Parkinson's disease. 2015 , 30, 121-7	203
720	Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment. 2015 , 262, 7-20	15
719	COMT Associations with Disordered Gambling and Drinking Measures. 2015 , 31, 513-24	16
718	Dopaminergic Medication in Parkinson's Disease and Problem Gambling. 2015 , 31, 1085-106	5
717	Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder. 2015 , 86, 174-9	52
716	Failure of stop and go in de novo Parkinson's disease--a functional magnetic resonance imaging study. 2015 , 36, 470-5	33
715	Oral and infusion levodopa therapy in the management of Parkinson's disease. 63-75	
714	Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease. 325-336	
713	Management of treatment-related behavioral disturbances in Parkinson's disease. 139-150	
712	Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease. 231-241	
711	The pharmacological basis of Parkinson's disease therapy: an overview. 1-4	
710	National Trends of Antiparkinsonism Treatment in Taiwan: 2004-2011. 2016 , 2016, 1859321	6
709	Impact of Sex on the Nonmotor Symptoms and the Health-Related Quality of Life in Parkinson's Disease. 2016 , 2016, 7951840	29
708	Oral dopamine agonists in the management of Parkinson's disease. 34-47	
707	Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's Disease. 2016 , 8, 68	35

706	Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?. 2016 , 10, 16	9
705	Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers. 2016 , 10, 523	7
704	Parkinson Disease. 2016 , 34, 300-7	28
703	Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?. 2016 , 7, 91	18
702	Introduction to Parkinson disease (PD) and its complications. 2016 , 6, 229-235	4
701	Imaging the Gambling Brain. 2016 , 129, 111-24	3
700	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. 2016 , 23, 1255-61	58
699	Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease. 2016 , 22, 167-77	12
698	Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. 2016 , 87, 1106-11	70
697	Impulse Control Disorders - The Continuum Hypothesis. 2016 , 6, 67-75	5
696	Publicity and reports of behavioral addictions associated with dopamine agonists. 2016 , 5, 140-143	8
695	Management of impulse control disorders in Parkinson's disease. 2016 , 28, 1597-614	12
694	Hospital care for mental health and substance abuse conditions in Parkinson's disease. 2016 , 31, 1810-1819	8
693	Apomorphine therapy in Parkinson's and future directions. 2016 , 33 Suppl 1, S56-S60	18
692	Managing cognition in progressive supranuclear palsy. 2016 , 6, 499-508	27
691	Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease. 2016 , 31, 231-238	4
690	Multi-faceted impulsivity following nigral degeneration and dopamine replacement therapy. 2016 , 109, 69-77	20
689	Neuropsychiatric Issues in Parkinson's Disease. 2016 , 16, 49	53

688	Executive functioning and risk-taking behavior in Parkinson's disease patients with impulse control disorders. 2016 , 123, 573-81	12
687	How close are we to individualized medicine for Parkinson's disease?. 2016 , 16, 815-30	19
686	Brainjacking: Implant Security Issues in Invasive Neuromodulation. 2016 , 92, 454-462	59
685	Impulsive-compulsive behaviors in parkin-associated Parkinson disease. 2016 , 87, 1436-1441	41
684	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. 2016 , 23, 1556-65	42
683	Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis. 2016 , 41, 3161-3170	15
682	Impulse control disorders in patients with young-onset Parkinson's disease: A cross-sectional study seeking associated factors. 2016 , 6, 197-205	2
681	The Implications of Parkinson's Disease for Women's Health. 2016 , 45, 723-36	1
680	A multidimensional approach to impulsivity in Parkinson's disease: measurement and structural invariance of the UPPS Impulsive Behaviour Scale. 2016 , 46, 2931-2941	8
679	Impulse control disorders in Parkinson's disease: Predominant role of psychological determinants. 2016 , 31, 1391-1414	8
678	Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited. 2016 , 172, 512-523	5
677	Impacts of religious semantic priming on an intertemporal discounting task: Response time effects and neural correlates. 2016 , 89, 403-413	4
676	Parkinson's Impulse-Control Scale for the Severity Rating of Impulse-Control Behaviors in Parkinson's Disease: A Semistructured Clinical Assessment Tool. 2016 , 3, 494-499	21
675	The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication. 2016 , 91, 163-172	27
674	Psychiatric and Cognitive Effects of Deep Brain Stimulation for Parkinson's Disease. 2016 , 16, 87	13
673	Advances in dopamine receptor agonists for the treatment of Parkinson's disease. 2016 , 17, 1889-902	26
672	Relationship between impulsivity traits and awareness of motor intention. 2016 , 44, 2455-2459	7
671	Uroneurology. 2016 , 967-983	1

670	Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson's disease. 2016 , 6, 267-77	25
669	Impulse Control Disorders in Parkinson's Disease are Associated with Alterations in Reward-Related Cortical Oscillations. 2016 , 6, 651-66	4
668	Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care. 2016 , 24, 1171-1180	22
667	A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease. 2016 , 30, 957-66	1
666	Hypersexuality induced by rasagiline in monotherapy in Parkinson's disease. 2016 , 37, 1889-1890	7
665	Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients. 2016 , 12, 41-6	14
664	Unmasking levodopa resistance in Parkinson's disease. 2016 , 31, 1602-1609	51
663	The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations. 2016 , 31, 1080-94	84
662	Future Targets for Female Sexual Dysfunction. 2016 , 13, 1147-65	14
661	The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. 2016 , 368, 150-4	96
660	Neurobiological Basis of Hypersexuality. 2016 , 129, 67-83	33
659	Behavioral and Pharmacological Treatment of Compulsive Sexual Behavior/Problematic Hypersexuality. 2016 , 3, 406-413	2
658	Profile of Neuropsychiatric Symptoms in Parkinson's Disease: Surgical Candidates Compared to Controls. 2016 , 6, 133-42	13
657	Management of erectile dysfunction in neurological patients. 2016 , 220-228	1
656	Management of autonomic dysfunction in Parkinson's disease. 93-110	2
655	Should compulsive sexual behavior be considered an addiction?. 2016 , 111, 2097-2106	224
654	Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. 2016 , 30, 13-7	35
653	Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease. 2016 , 29, 96-103	14

652	Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease. 2016 , 70, 77-84	19
651	Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault?. 2016 , 366, 167-170	11
650	Desenmascaramos los sñtomas extramotores de la enfermedad de Parkinson. 2016 , 33, 20-25	
649	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. 2016 , 139, 161-73	51
648	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. 2016 , 31, 270-9	44
647	Cortico-basal ganglia circuits involved in different motivation disorders in non-human primates. 2016 , 221, 345-64	20
646	Neurobiology of Compulsive Sexual Behavior: Emerging Science. 2016 , 41, 385-6	32
645	Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders. 2016 , 29, 72-91	7
644	A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. 2016 , 15, 181-98	18
643	Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole. 2016 , 28, 909-19	19
642	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. 2016 , 37, 1026-37	42
641	Jumping to conclusions in untreated patients with Parkinson's disease. 2016 , 85, 19-23	12
640	The 5-HT2A serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseases. 2016 , 64, 63-82	41
639	The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. 2016 , 16, 245-58	16
638	Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. 2016 , 25, 41-5	30
637	Dopamine improves exploration after expectancy violations and induces psychotic-like experiences in patients with Parkinson's disease. 2016 , 616, 132-7	4
636	Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions. 2016 , 16, 389-99	20
635	The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review. 2016 , 25, 10-6	39

634	A survey of impulse control disorders in Parkinson's disease patients in Shanghai area and literature review. 2016 , 5, 4	12
633	Cognitive and Psychiatric Disturbances in Parkinsonian Syndromes. 2016 , 34, 235-46	10
632	"Rescue" of bilateral subthalamic stimulation by bilateral pallidal stimulation: case report. 2016 , 124, 417-21	13
631	Inhibition of hippocampal plasticity in rats performing contrafreeloading for water under repeated administrations of pramipexole. 2016 , 233, 727-37	3
630	Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. 2016 , 87, 864-70	76
629	[Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease]. 2016 , 31, 231-8	16
628	Molecular imaging and neural networks in impulse control disorders in Parkinson's disease. 2016 , 22 Suppl 1, S101-5	21
627	Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease. 2017 , 32, 494-499	6
626	Integrating Patient Concerns into Parkinson's Disease Management. 2017 , 17, 3	28
625	Management of impulse control disorders with deep brain stimulation: A double-edged sword. 2017 , 374, 63-68	19
624	Phenomenology and epidemiology of impulsive-compulsive behaviours in Parkinson's disease, atypical Parkinsonian disorders and non-Parkinsonian populations. 2017 , 374, 47-52	19
623	[No motor signs in Parkinson's disease]. 2017 , 46, 195-201	4
622	Algorithms for the treatment of motor problems in Parkinson's disease. 2017 , 136, 378-385	24
621	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. 2017 , 32, 181-192	56
620	Evidence of functional duplicity of Nestin expression in the adult mouse midbrain. 2017 , 19, 82-93	12
619	Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study. 2017 , 7, 183-191	35
618	Cognitive-behavioural therapy for non-motor symptoms of Parkinson's disease: a clinical review. 2017 , 20, 15-20	52
617	Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. 2017 , 16, 238-250	207

616	Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including L-Dopa. 2017 , 132, 295-343	14
615	Is there a role for ghrelin in central dopaminergic systems? Focus on nigrostriatal and mesocorticolimbic pathways. 2017 , 73, 255-275	26
614	Nonmotor Effects of Conventional and Transdermal Dopaminergic Therapies in Parkinson's Disease. 2017 , 134, 989-1018	10
613	Differences and Similarities Between Compulsive Buying and Other Addictive Behaviors. 2017 , 4, 228-236	18
612	Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease. 2017 , 31, 1323-1333	6
611	Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective. 2017 , 17, 737-749	4
610	Personalized medicine in Parkinson's disease: Time to be precise. 2017 , 32, 1147-1154	78
609	A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. 2017 , 32, 783-789	16
608	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. 2017 , 88, 317-324	82
607	Effects of deep brain stimulation of the subthalamic nucleus on perceptual decision making. 2017 , 343, 140-146	5
606	Impulse control disorder, lysosomal malfunction and ATP13A2 insufficiency in Parkinsonism. 2017 , 44, 172-179	3
605	Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?. 2017 , 32, 840-860	26
604	Cognitive and Neuropsychiatric Features of Early Parkinson's Disease. 2017 , 32, 769-785	25
603	Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. 2017 , 32, 1557-1565	50
602	Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease. 2017 , 32, 1710-1719	39
601	Genes and Nonmotor Symptoms in Parkinson's Disease. 2017 , 133, 111-127	6
600	Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease. 2017 , 32, 494-499	2
599	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. 2017 , 32, 1264-1310	375

598	Personalized Medicine and Nonmotor Symptoms in Parkinson's Disease. 2017 , 134, 1257-1281	30
597	Gender differences in Parkinson's disease: A clinical perspective. 2017 , 136, 570-584	77
596	Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease. 2017 , 32, 1566-1573	56
595	Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature. 2017 , 30, 235-252	115
594	Measures of impulsivity in Parkinson's disease decrease after DBS in the setting of stable dopamine therapy. 2017 , 44, 13-17	17
593	Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study. 2017 , 44, 6-12	8
592	Sexual Dysfunctions in Parkinson's Disease: An Underrated Problem in a Much Discussed Disorder. 2017 , 134, 859-876	23
591	Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. 2017 , 133, 389-415	7
590	Sexual Preoccupation Behavior in Parkinson's Disease. 2017 , 7, 175-182	12
589	Response to Commentaries: Recognizing Hypersexuality as a Psychosexual Behavioral Problem and Advancing the Sexhavior Cycle of Hypersexuality. 2017 , 46, 2279-2287	6
588	Dementia, Decision Making, and Capacity. 2017 , 25, 270-278	25
587	Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease. 2017 , 31, 551-570	30
586	Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area. 2017 , 332, 327-336	12
585	Hypersexuality: A Critical Review and Introduction to the "Sexhavior Cycle". 2017 , 46, 2231-2251	96
584	Deep Brain Stimulation and Nonmotor Symptoms. 2017 , 134, 1045-1089	10
583	Weight in Parkinson's Disease: Phenotypical Significance. 2017 , 134, 891-919	13
582	Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects. 2017 , 3, 23	26
581	Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. 2017 , 94, 63-72	40

580	Clinical characteristics of impulse control and related disorders in Chinese Parkinson's disease patients. 2017 , 17, 98	12
579	Impulse Control and Related Disorders in Parkinson's Disease. 2017 , 133, 679-717	136
578	Phenomenology and gender characteristics of hobbyism and punning in Parkinson's disease: A self-report study. 2017 , 9, 1-6	2
577	Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. 2017 , 264, 40-48	41
576	Impaired learning of punishments in Parkinson's disease with and without impulse control disorder. 2017 , 124, 217-225	10
575	The impact of Parkinson disease on patients' sexuality and relationship. 2017 , 124, 983-996	20
574	Dysexecutive syndrome in Parkinson's disease: the GREFEX study. 2017 , 24, 496-507	8
573	Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications. 2017 , 234, 15-27	6
572	Modafinil alters decision making based on feedback history - a randomized placebo-controlled double blind study in humans. 2017 , 31, 243-249	6
571	A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps. 2017 , 4, 323-328	23
570	Chronic D agonist ropinirole treatment increases preference for uncertainty in rats regardless of baseline choice patterns. 2017 , 45, 159-166	29
569	Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release. 2017 , 114, 77-87	16
568	Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating. 2017 , 42, 1169-1177	96
567	Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?. 2017 , 45, 67-72	22
566	Neuropsychiatric symptoms in untreated Parkinson's disease. 2017 , 13, 815-826	25
565	Dementias and the Frontal Lobes. 2017 , 445-486	1
564	Impulsivity in Patients with Parkinson's Disease. 2017 , 10, 3-8	
563	Involuntary Movement Disorders. 2017 , 389-447	

562	Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson's Disease. 2017 , 11, 145	21
561	Decision-Making and Impulse Control Disorders in Parkinson's Disease. 2017 , 305-314	5
560	Impulse control disorders in Parkinson's disease. 2018 , 125, 1299-1312	17
559	Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. 2018 , 373, 111-135	27
558	Risk factors for non-motor symptoms in Parkinson's disease. 2018 , 17, 559-568	108
557	Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations. 2018 , 8, e00904	9
556	Brain PET substrate of impulse control disorders in Parkinson's disease: A metabolic connectivity study. 2018 , 39, 3178-3186	22
555	Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. 2018 , 187, 134-140	39
554	Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease: A systematic review. 2018 , 28, 561-578	6
553	Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease. 2018 , 66, 12-22	17
552	Current perspectives on incentive salience and applications to clinical disorders. 2018 , 22, 59-69	79
551	The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks. 2018 , 373, 327-336	24
550	Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: results from a long-term follow-up cohort study. 2018 , 89, 836-843	36
549	Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. 2018 , 7, R88-R94	10
548	Dyskinesias and levodopa therapy: why wait?. 2018 , 125, 1119-1130	9
547	Compulsive sexual behaviour disorder in the ICD-11. 2018 , 17, 109-110	225
546	Closing the loop on impulsivity via nucleus accumbens delta-band activity in mice and man. 2018 , 115, 192-197	51
545	The Role of a Neuropsychologist on a Movement Disorders Deep Brain Stimulation Team. 2018 , 33, 365-374	6

544	Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey. 2018 , 365, 379-397	23
543	Reward sensitivity in Parkinson's patients with binge eating. 2018 , 51, 79-84	6
542	Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease. 2018 , 265, 1279-1287	14
541	A multifactorial and integrative approach to impulsivity in neuropsychology: insights from the UPPS model of impulsivity. 2018 , 40, 45-61	33
540	Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease. 2018 , 23, 459-466	38
539	Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease. 2018 , 46 Suppl 1, S15-S18	14
538	The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. 2018 , 5, 6-13	14
537	Dopamine Agonists and Impulse Control Disorders: A Complex Association. 2018 , 41, 19-75	57
536	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. 2018 , 47, 50-56	12
535	Compulsive sexual behaviour in Parkinson's disease is associated with higher doses of levodopa. 2018 , 89, 1121-1123	5
534	The rise and fall of impulse control behavior disorders. 2018 , 46 Suppl 1, S24-S29	22
533	Dopaminagonisten spielen eine Schlüsselrolle. 2018 , 20, 20-21	
532	Impulse Control Behaviors in Parkinson's Disease: Drugs or Disease? Contribution From Imaging Studies. 2018 , 9, 893	8
531	Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. 2018 , 33, 1878-1886	22
530	Nigrostriatal Dopaminergic Denervation Does Not Promote Impulsive Choice in the Rat: Implication for Impulse Control Disorders in Parkinson's Disease. 2018 , 12, 312	5
529	DBS and Impulse Control Disorders in PD: I think we got this! wait! we don't. 2018 , 56, 1-2	0
528	Advances in Parkinson's Disease: 200 Years Later. 2018 , 12, 113	65
527	Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. 2018 , 9, 1041	6

526	An Integrative Biopsychosocial and Sex Positive Model of Understanding and Treatment of Impulsive/Compulsive Sexual Behavior. 2018 , 25, 125-152	19
525	Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies. 2018 , 9, 1018	19
524	Impulse Control Disorder in Parkinson's Disease: A Meta-Analysis of Cognitive, Affective, and Motivational Correlates. 2018 , 9, 654	28
523	A Current Understanding of the Behavioral Neuroscience of Compulsive Sexual Behavior Disorder and Problematic Pornography Use. 2018 , 5, 218-231	80
522	Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?. 2018 , 18, 91	4
521	Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease. 2018 , 141, 365-404	
520	Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity. 2018 , 9, 465	14
519	Dysexecutive disorders and their diagnosis: A position paper. 2018 , 109, 322-335	21
518	Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review. 2018 , 174, 653-663	36
517	Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. 2018 , 62, 692-700	13
516	Relationships between activity and well-being in people with parkinson's disease. 2018 , 8, e00976	5
515	Symptoms and medications change patterns for Parkinson's disease patients stratification. 2018 , 91, 82-95	12
514	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. 2018 , 53, 108-109	0
513	Demographic and Clinical Predictors of Trait Impulsivity in Parkinson's Disease Patients. 2018 , 2018, 9472120	11
512	Psychological functioning in Parkinson's disease post-deep brain stimulation: Self-regulation and executive functioning. 2018 , 111, 42-49	4
511	The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study. 2018 , 8, e01036	14
510	Deep Brain Stimulation of the Internal Globus Pallidus Improves Response Initiation and Proactive Inhibition in Patients With Parkinson's Disease. 2018 , 9, 351	3
509	The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery. 2018 , 10, 18	13

508	A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. 2018 , 56, 3-8	16
507	Delusions in Parkinson's Disease: A Systematic Review of Published Cases. 2018 , 28, 310-316	13
506	Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson's Disease. 2018 , 9, 109	18
505	White Matter Tract Alterations in Drug-Naïve Parkinson's Disease Patients With Impulse Control Disorders. 2018 , 9, 163	13
504	Impulsivity in Parkinson's Disease Is Associated With Alterations in Affective and Sensorimotor Striatal Networks. 2018 , 9, 279	17
503	Impulse-Control Disorders in Parkinson's Disease: A Meta-Analysis and Review of Case-Control Studies. 2018 , 9, 330	26
502	Closed Loop Deep Brain Stimulation for PTSD, Addiction, and Disorders of Affective Facial Interpretation: Review and Discussion of Potential Biomarkers and Stimulation Paradigms. 2018 , 12, 300	15
501	Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias. 2018 , 265, 2088-2096	15
500	Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. 2018 , 32, 621-635	21
499	Risky decision-making and affective features of impulse control disorders in Parkinson's disease. 2018 , 125, 131-143	4
498	Sleep in Parkinson's Disease with Impulse Control Disorder. 2018 , 18, 68	4
497	Impulse control and related disorders in Parkinson's disease. 2018 , 76, 399-410	9
496	Special issue "Parkinson's disease". 2018 , 373, 1-7	7
495	Longitudinal analysis of impulse control disorders in Parkinson disease. 2018 , 91, e189-e201	123
494	Dopamine Receptor D3 rs6280 is Associated with Aberrant Decision-Making in Parkinson's Disease. 2018 , 5, 413-416	6
493	Neuropsychopharmacological aesthetics: A theoretical consideration of pharmacological approaches to causative brain study in aesthetics and art. 2018 , 237, 343-372	9
492	Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decision-making. 2019 , 50, 2392-2400	4
491	Addressing sexuality and intimacy in people living with Parkinson's during palliative care and at the end of life. 2019 , 28, 772-779	1

490	Brain Imaging and Impulse Control Disorders in Parkinson’s Disease. 2019 , 19, 67	4
489	Molecular imaging of impulse control disorders in Parkinson’s disease. 2019 , 46, 2220-2222	2
488	Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease. 2019 , 86, 762-769	12
487	Gambling disorder. 2019 , 5, 51	132
486	Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinson’s Disease Patients. 2019 , 9, 625-630	5
485	Impulse control disorders in Parkinson disease and RBD: A longitudinal study of severity. 2019 , 93, e675-e687	24
484	Deep Brain Stimulation for Parkinson’s Disease. 2019 , 291-303	
483	Parkinson’s Disease in Women and Men: What’s the Difference?. 2019 , 9, 501-515	104
482	Pragmatism and the Importance of Interdisciplinary Teams in Investigating Personality Changes following DBS. 2019 , 2019, 1	14
481	Dual-mode dopamine increases mediated by 5-HT and 5-HT receptors inhibition, inducing impulsive behavior in trained rats. 2019 , 237, 2573-2584	2
480	Impulse control symptoms in patients with Parkinson’s disease: The influence of dopaminergic agonist. 2019 , 68, 17-21	6
479	Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders. 2019 , 46, 2065-2076	6
478	Changes in Prescribing Practices of Dopaminergic Medications in Individuals with Parkinson’s Disease by Expert Care Centers from 2010 to 2017: The Parkinson’s Foundation Quality Improvement Initiative. 2019 , 6, 687-692	7
477	Risk factors for impulse control disorders and related behaviors in Parkinson’s disease: secondary analyses of the ICARUS study. 2019 , 8, 159-166	3
476	Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics. 2019 , 165, 83-121	9
475	Trait Impulsivity Is Independent of Mild Cognitive Impairment in a Parkinson’s Disease Cohort. 2019 , 2019, 2672075	3
474	The structural connectivity of discrete networks underlies impulsivity and gambling in Parkinson’s disease. 2019 , 142, 3917-3935	22
473	Why would Parkinson’s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses. 2019 , 100, 129-165	9

472	Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner. 2019 , 66, 189-194	0
471	Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease. 2019 , 10, 972	1
470	Dopamine and the motivation of cognitive control. 2019 , 163, 123-143	30
469	Neural bases of impulse control disorders in Parkinson's disease: A systematic review and an ALE meta-analysis. 2019 , 107, 672-685	8
468	Resting state oscillations suggest a motor component of Parkinson's Impulse Control Disorders. 2019 , 130, 2065-2075	3
467	Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). 2019 , 6, 227-234	17
466	Impulse control disorders in Parkinson's disease: A systematic review on risk factors and pathophysiology. 2019 , 398, 101-106	19
465	Treatment of Impulse Control Disorders and Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. 2019 , 121-123	
464	Treatment of Dopamine Dysregulation Syndrome and Impulse Control Disorders in Parkinson's Disease. 2019 , 125-127	1
463	Editing the Central Nervous System Through CRISPR/Cas9 Systems. 2019 , 12, 110	20
462	Impulse control disorders in Parkinson's disease: A systematic review on the psychometric properties of the existing measures. 2019 , 14, e0217700	3
461	Cognitive and behavioral assessment in Parkinson's disease. 2019 , 19, 613-622	4
460	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. 2019 , 34, 791-798	25
459	Neuropsychiatric aspects of Parkinson's disease. 2019 , 126, 889-896	16
458	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. 2019 , 65, 39-48	23
457	Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease. 2019 , 707, 134313	6
456	Parkinson's disease management and impulse control disorders: current state and future perspectives. 2019 , 19, 495-508	6
455	Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. 2019 , 104, 2527-2534	24

454	Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review. 2019 , 10, 351	40
453	Movement Disorders. 2019 , 459-536	
452	Impulsive-Compulsive Behaviours in Belgian-Flemish Parkinson's Disease Patients: A Questionnaire-Based Study. 2019 , 2019, 7832487	1
451	Woe Betides Anybody Who Tries to Turn me Down. A Qualitative Analysis of Neuropsychiatric Symptoms Following Subthalamic Deep Brain Stimulation for Parkinson's Disease. 2019 , 1	12
450	Screening for Problematic Internet Use May Help Identify Impulse Control Disorders in Parkinson's Disease. 2019 , 2019, 4925015	6
449	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. 2019 , 27, 998-1018	44
448	Circuit Mechanisms of Parkinson's Disease. 2019 , 101, 1042-1056	119
447	Creativity related to dopaminergic treatment: A multicenter study. 2019 , 63, 169-173	7
446	Impulse control disorders in Parkinson's disease: A 20-year odyssey. 2019 , 34, 447-452	8
445	Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease. 2019 , 10, 266	6
444	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). 2019 , 63, 117-123	6
443	Impulse Control Disorders in REM Sleep Behavior Disorder. 2019 , 21, 23	4
442	Neurobiology and clinical features of impulse control failure in Parkinson's disease. 2019 , 1, 9	1
441	Are All Dopamine Agonists Essentially the Same?. 2019 , 79, 693-703	13
440	Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco. 2019 , 175, 233-237	11
439	Parkinson's disease, dopamine, and eating and weight disorders: an illness in the disease?. 2019 , 24, 383-384	2
438	Compulsive eating behaviors in Parkinson's disease. 2019 , 24, 421-429	9
437	The effect of dopamine on response inhibition in Parkinson's disease relates to age-dependent patterns of nigrostriatal degeneration. 2019 , 63, 185-190	6

436	Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease. 2019 , 10, 86	27
435	Multimodal MRI evaluation of parkinsonian limbic pathologies. 2019 , 76, 194-200	5
434	Medications and Cognition in Older Adults. 2019 , 147-168	
433	Movement Disorders with Dementia in Older Adults. 2019 , 543-575	
432	Current treatment of behavioral and cognitive symptoms of Parkinson's disease. 2019 , 59, 65-73	14
431	Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment. 2019 , 14, e0210880	6
430	Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinson's Disease. 2019 , 19, 171-177	2
429	Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review. 2019 , 2019, 9237181	7
428	Self-reported and experimentally induced self-disgust is heightened in Parkinson's disease: Contribution of behavioural symptoms. 2019 , 14, e0223663	4
427	The multifaceted nature of impulsivity in Parkinson's disease. 2019 , 142, 3666-3669	1
426	Genetic and environmental influences on gambling disorder liability: a replication and combined analysis of two twin studies. 2019 , 49, 1705-1712	4
425	Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease. 2019 , 142, 146-162	14
424	Patient with Parkinson's disease presenting with impulse control disorders following treatment with selegiline. 2019 , 31, 1375-1376	1
423	Regularly monitor neuropsychiatric symptoms in Parkinson's disease and adjust treatment as necessary. 2019 , 35, 119-123	
422	Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease. 2019 , 75, 126-135	11
421	Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease. 2019 , 61, 111-117	12
420	The role of dopamine in the brain - lessons learned from Parkinson's disease. 2019 , 190, 79-93	65
419	Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease. 2019 , 126, 377-396	10

418	Genetic and Environmental Contributions to Risk for Disordered Gambling. 2019 , 73-100	4
417	Functional imaging studies of Impulse Control Disorders in Parkinson's disease need a stronger neurocognitive footing. 2019 , 98, 164-176	8
416	Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. 2019 , 90, 30-37	12
415	Impulse control disorders in Parkinson's disease: a hard-turning point. 2019 , 90, 2	2
414	Pharmacological insights into impulsive-compulsive spectrum disorders associated with dopaminergic therapy. 2019 , 50, 2492-2502	4
413	Role of clinical neuropsychology in deep brain stimulation: Review of the literature and considerations for clinicians. 2019 , 26, 283-296	5
412	Capacity, control and responsibility in Parkinson's disease patients with impulse control disorders: Views of neurological and psychiatric experts. 2019 , 65, 101343	
411	Iowa Gambling Task Performance in Parkinson Disease Patients with Impulse Control Disorders. 2019 , 34, 310-318	9
410	Assessing inhibitory control in early-stage Alzheimer's and Parkinson's disease using the Hayling Sentence Completion Test. 2019 , 13, 67-81	11
409	Mechanisms Underlying Dopamine-Induced Risky Choice in Parkinson's Disease With and Without Depression (History). 2018 , 2, 11-27	8
408	Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson's disease. 2020 , 14, 2785-2798	2
407	Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. 2020 , 36, 85-96	4
406	Interaction of Cannabis Use and Aging: From Molecule to Mind. 2020 , 16, 140-176	4
405	Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. 2020 , 105,	18
404	Evolution of impulsive-compulsive behaviors and cognition in Parkinson's disease. 2020 , 267, 259-266	3
403	Impulse control disorders in Parkinson's disease versus in healthy controls: A different predictive model. 2020 , 14, 318-332	2
402	Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease. 2020 , 35, 316-325	10
401	What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson's disease? A preliminary pharmacoepidemiologic study. 2020 , 15, e0227128	5

400	Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders. 2020 , 47, 2165-2174	3
399	Dynamics of impulsive-compulsive behaviors in early Parkinson's disease: a prospective study. 2020 , 267, 1127-1136	8
398	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. 2020 , 36, 105-118	13
397	Frequency of non-motor symptoms and their impact on the quality of life in patients with Parkinson's disease: a prospective descriptive case series. 2020 , 20, 206-211	5
396	The anterior caudate nucleus supports impulsive choices triggered by pramipexole. 2020 , 35, 296-305	2
395	Using rodent models to understand interactions between gambling and substance use. 2020 , 31, 37-41	1
394	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. 2020 , 57, 100994	28
393	Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies. 2020 , 78, 165-177	4
392	Longitudinal association between dopamine agonists and weight in Parkinson's disease. 2020 , 80, 158-164	1
391	Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson's disease. 2020 , 28, 102362	0
390	Hypersexuality associated with safinamide. 2020 , 35, 534-535	1
389	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. 2020 , 10, 16893	2
388	Linking brain activity during sequential gambling to impulse control in Parkinson's disease. 2020 , 27, 102330	4
387	Young Onset Parkinson's Disease: A Modern and Tailored Approach. 2020 , 10, S29-S36	13
386	Foreword. 2020 , xii-xiv	
385	Concepts of Addiction. 2020 , 1-50	
384	Appetitive Needs and Addiction. 2020 , 3-11	8
383	Behavioral Economics and Addictive Disorders. 2020 , 12-22	40

382	Sensitization of Incentive Salience and the Transition to Addiction. 2020 , 23-37	40
381	Philosophical Issues in the Addictions. 2020 , 38-50	
380	Clinical and Research Methods in the Addictions. 2020 , 51-118	
379	Human Neurobiological Approaches to Hedonically Motivated Behaviors. 2020 , 53-61	40
378	Human Laboratory Paradigms in Addictions Research. 2020 , 62-72	
377	Behavioral Economic Considerations of Novel Addictions and Nonaddictive Behavior: Research and Analytic Methods. 2020 , 73-86	40
376	Substance and Behavioral Addictions Assessment Instruments. 2020 , 87-105	1
375	Qualitative Approaches to the Study of Substance and Behavioral Addictions. 2020 , 106-118	1
374	Levels of Analysis and Etiology. 2020 , 119-198	
373	Neurobiology of Substance Addictions. 2020 , 121-135	40
372	Neurobiological Foundations of Behavioral Addictions. 2020 , 136-151	40
371	Multiple Memory Systems, Addiction, and Health Habits: New Routes for Translational Science. 2020 , 152-170	40
370	The Role of Culture in Addiction. 2020 , 171-181	2
369	The Physical and Social Environments as Determinants of Health: Implications for Substance and Behavioral Addictions. 2020 , 182-198	
368	Prevention and Treatment. 2020 , 199-294	
367	Adolescent Drug Misuse Prevention: Challenges in School-Based Programming. 2020 , 201-214	1
366	Treatment of Alcohol, Tobacco, and Other Drug (ATOD) Misuse. 2020 , 215-229	2
365	Prevention and Treatment of Food Addiction 2020 , 230-240	40

364	The Prevention and Treatment of Gambling Disorders: Some Art, Some Science. 2020 , 241-253	42
363	Prevention and Treatment of Sex Addiction. 2020 , 254-261	1
362	Passionate Love Addiction: An Evolutionary Survival Mechanism That Can Go Terribly Wrong. 2020 , 262-270	
361	Prevention and Treatment of Compulsive Buying Disorder. 2020 , 271-279	40
360	Prevention and Treatment of Work Addiction. 2020 , 280-287	
359	Gaming Disorder and Its Treatment. 2020 , 288-294	1
358	Ongoing and Future Research Directions. 2020 , 295-425	
357	Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis. 2020 , 297-306	40
356	Novel Psychoactive Substances: A New Challenge for Prevention and Treatment. 2020 , 307-325	
355	Impaired Physicians. 2020 , 326-332	
354	Feedback Models for Gambling Control: The Use and Efficacy of Online Responsible Gambling Tools. 2020 , 333-339	40
353	Food versus Eating Addictions. 2020 , 340-351	40
352	Measurement, Prevention, and Treatment of Exercise Addiction. 2020 , 352-361	
351	Tanning as an Addiction: The State of the Research and Implications for Intervention. 2020 , 362-372	40
350	Considering the Overlap and Nonoverlap of Compulsivity, Impulsivity, and Addiction. 2020 , 373-385	41
349	Anhedonia in Addictive Behaviors. 2020 , 386-408	
348	Mindfulness-Based Interventions Applied to Addiction Treatments. 2020 , 409-417	40
347	American Legal Issues in Addiction Treatment and Research. 2020 , 418-425	

346	Index. 2020 , 426-446	
345	Increased large-scale inter-network connectivity in relation to impulsivity in Parkinson's disease. 2020 , 10, 11418	5
344	Accelerated habitual learning resulting from L-dopa exposure in rats is prevented by N-acetylcysteine. 2020 , 198, 173033	5
343	Changes in Self- and Informant-Reported Frontal Behaviors in Parkinson's Disease: A Longitudinal Study. 2022 , 35, 89-101	1
342	'Dopamine agonist Phobia' in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicine. 2020 , 20, 953-965	3
341	Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. 2020 , 143, 2502-2518	16
340	Pavlovian bias in Parkinson's disease: an objective marker of impulsivity that modulates with deep brain stimulation. 2020 , 10, 13448	2
339	Exome Sequencing Reveals Signal Transduction Genes Involved in Impulse Control Disorders in Parkinson's Disease. 2020 , 11, 641	3
338	The accuracy of self-report logbooks of adherence to prescribed home-based exercise in Parkinson's disease. 2020 , 1-8	1
337	Cognitive and behavioural inhibition deficits in neurodegenerative dementias. 2020 , 131, 265-283	8
336	Preface. 2020 , xiii-xv	
335	Editors' Note. 2020 , xvii-xvii	
334	Sexual addiction 25 years on: A systematic and methodological review of empirical literature and an agenda for future research. 2020 , 82, 101925	55
333	What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. 2020 , 202-212	
332	Epidemiology and Mental Health in Old Age. 2020 , 5-23	
331	Vascular Dementia. 2020 , 24-37	
330	Young-Onset Dementias. 2020 , 38-49	
329	Rare and Unusual Dementias. 2020 , 50-77	

328 Mania in Late Life. **2020**, 78-91

327 Alcohol Misuse in Older People. **2020**, 92-104

326 Drug Misuse in Older People. **2020**, 105-115

325 Mental Health in Parkinson's Disease. **2020**, 116-128

324 The Home Assessment in Old Age Psychiatry. **2020**, 129-138

323 Driving in Dementia. **2020**, 139-148

322 Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. **2020**, 149-160

321 Biomarkers and the Diagnosis of Preclinical Alzheimer's Disease. **2020**, 161-172

320 To Scan or Not to Scan. **2020**, 173-190

319 Supporting Self-Management in Early Dementia. **2020**, 191-201

318 Psychosocial Interventions in Dementia. **2020**, 213-222

317 Palliative Care in Dementia. **2020**, 223-242

316 Review of Treatment for Late-Life Depression. **2020**, 243-253

315 Reducing the Healthcare Burden of Delirium. **2020**, 254-265

314 Controlling the Confusion. **2020**, 266-278

313 Residence Capacity. **2020**, 305-316

312 Concluding Reflections. **2020**, 328-329

311 Index. **2020**, 330-344

310	Introductory Comments. 2020 , 1-4	
309	Mental Health Laws from All UK Jurisdictions. 2020 , 279-292	
308	Deprivation of Liberty. 2020 , 293-304	
307	Understanding the Person with Dementia. 2020 , 317-327	
306	The experiences of carers looking after people with Parkinson's disease who exhibit impulsive and compulsive behaviours: An exploratory qualitative study. 2020 , 29, 4623-4632	1
305	An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease. 2020 , 21, 2279-2291	3
304	Inhibitory control dysfunction in parkinsonian impulse control disorders. 2020 , 143, 3734-3747	5
303	Istradefylline to Treat Patients with Parkinson's Disease Experiencing "Off" Episodes: A Comprehensive Review. 2020 , 12, 109-129	6
302	I Don't Know When to Stop. 2020 , 149-152	
301	Elevated Serum Ceruloplasmin Levels Are Associated with Higher Impulsivity in People with Parkinson's Disease. 2020 , 2020, 8296203	2
300	Spectrum of impulse control behaviours in Parkinson's disease: pathophysiology and management. 2020 , 91, 703-711	14
299	Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation. 2020 , 267, 2443-2454	1
298	Lewy Body Degenerations as Neuropsychiatric Disorders. 2020 , 43, 361-381	2
297	Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease?. 2020 , 88, 759-770	6
296	Neurobiology of cue-reactivity, craving, and inhibitory control in non-substance addictive behaviors. 2020 , 415, 116952	24
295	The role of dopaminergic and serotonergic transmission in the processing of primary and monetary reward. 2020 , 45, 1490-1497	1
294	The Impact of Deep Brain Stimulation on the Sexual Function of Patients With Parkinson's Disease. 2020 , 25, 55-61	3
293	Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics. 2020 , 17, 1511-1524	9

292	MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease. 2020 , 35, 724-740	3
291	Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. 2020 , 29, 591-598	3
290	Excessive charity: A new aspect of impulse control disorders in Parkinson's disease?. 2020 , 1-2	
289	Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment. 2020 , 26, 333-342	3
288	Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?. 2020 , 14, 25	15
287	Measurement properties from the Brazilian Portuguese version of the QUIP-RS. 2020 , 6, 6	4
286	Impulse control and related behaviors in Parkinson's disease with dementia. 2020 , 27, 944-950	10
285	Behavioral and Neuroanatomical Account of Impulsivity in Parkinson's Disease. 2019 , 10, 1338	10
284	Hypersexuality associated with safinamide. 2020 , 35, 534-535	1
283	Ethnic Variation in the Manifestation of Parkinson's Disease: A Narrative Review. 2020 , 10, 31-45	22
282	Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease. 2020 , 35, 616-628	10
281	The adverse effects of pramipexole on probability discounting are not reversed by acute D or D receptor antagonism. 2020 , 32, 104-119	3
280	Self-reported rates of impulsivity in Parkinson's Disease. 2020 , 7, 437-448	5
279	The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease. 2020 , 102, 109942	13
278	Measuring impulsivity in Parkinson's disease: a correlational and structural neuroimaging study using different tests. 2020 , 27, 1478-1486	2
277	Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation. 2020 , 10, 927-934	3
276	DBS: a compelling example for ethical and legal reflection-a French perspective on ethical and legal concerns about DBS. 2020 , 38, 15-34	
275	From apathy to addiction: Insights from neurology and psychiatry. 2020 , 101, 109926	9

274	Parkinson's disease and osteoporosis: basic and clinical implications. 2020 , 15, 185-193	4
273	Evolution of Initial Pharmacologic Treatment of Newly Diagnosed Parkinson's Disease Patients over a Decade in Singapore. 2020 , 2020, 6293124	1
272	Integrating genetic and clinical data to predict impulse control disorders in Parkinson's disease. 2021 , 28, 459-468	5
271	Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease. 2021 , 108, 110184	3
270	Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review. 2021 , 8, 25-32	5
269	Disease progression and phenotypes of non-motor symptoms in Parkinson's disease. 2021 , 9, 83-90	1
268	Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. 2021 , 44, 1699-1706	4
267	The Role of ADHD Symptomatology and Emotion Dysregulation in Gambling Disorder. 2021 , 25, 1230-1239	9
266	Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity. 2021 , 36, 1435-1440	0
265	Literaturverzeichnis. 2021 , 805-903	
264	The Digital Marshmallow Test (DMT) Diagnostic and Monitoring Mobile Health App for Impulsive Behavior: Development and Validation Study. 2021 , 9, e25018	5
263	Medical treatment of the motor features of Parkinson disease. 2021 , 164-203.e14	1
262	Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study. 2021 , 29, 206-212	1
261	Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience. 2021 , 35, 215-231	7
260	Sexual Disorders and Quality of Life in Parkinson's Disease. 2021 , 9, 100280	5
259	The clinical meaning of levodopa equivalent daily dose in Parkinson's disease. 2021 , 35, 620-630	3
258	Bidirectional Correlations Between Dopaminergic Function and Motivation in Parkinson's Disease. 2021 , 891988721996802	1
257	[Problematic gambling and criminal responsibility]. 2021 , 47, 43-48	1

256	Impulse control behavior in GBA-mutated parkinsonian patients. 2021 , 421, 117291	2
255	Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. 2021 , 12, 635494	3
254	The relationship between apathy and impulsivity in large population samples. 2021 , 11, 4830	4
253	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. 2021 , 144, 2513-2526	6
252	Impulse Control Disorders in Parkinson's Disease: From Bench to Bedside. 2021 , 15, 654238	2
251	Limbic hypoconnectivity in idiopathic REM sleep behaviour disorder with impulse control disorders. 2021 , 268, 3371-3380	1
250	Psychomotor Impairments and Therapeutic Implications Revealed by a Mutation Associated with Infantile Parkinsonism-Dystonia.	
249	Attentional dysfunction and the punding spectrum in Parkinson's disease. 2021 , 84, 23-28	3
248	Substantia nigra ferric overload and neuromelanin loss in Parkinson's disease measured with 7T MRI.	1
247	New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease. 2021 , 42, 2673-2682	1
246	Role of Occupational Therapy in Facilitating Participation Among Caregivers of People With Parkinson's Disease: A Systematic Review. 2021 , 75,	2
245	Aberrant Salient and Corticolimbic Connectivity in Hypersexual Parkinson's Disease. 2021 , 11, 639-650	3
244	Impulse control disorders and related behaviors in Parkinson's disease: risk factors, clinical and genetic aspects, and management. 2021 , 34, 547-555	0
243	Assessment of deep brain stimulation candidacy during the COVID-19 pandemic: Lessons learned and future directions for neuropsychologists. 2021 , 1-13	0
242	A case-control study investigating food addiction in Parkinson patients. 2021 , 11, 10934	1
241	Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-Dystonia. 2021 , 10,	5
240	Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden. 2021 , 16, e0252516	0
239	The Growing Role of Cognitive Behavior Therapy in the Treatment of Parkinson's Disease. 2021 , 34, 310-320	3

238	Objective assessment of impulse control disorder in patients with Parkinson's disease using a low-cost LEGO-like EEG headset: a feasibility study. 2021 , 18, 109	1
237	Changing Gears - DBS For Dopaminergic Desensitization in Parkinson's Disease?. 2021 , 90, 699-710	2
236	Does Personality Change Follow Deep Brain Stimulation in Parkinson's Disease Patients?. 2021 , 12, 643277	1
235	Impulse Control Disorders in Parkinson's Disease: Has COVID-19 Related Lockdown Been a Trigger?. 2021 , 8, 940-943	2
234	An association between prediction errors and risk-seeking: Theory and behavioral evidence. 2021 , 17, e1009213	1
233	Does antiretroviral therapy alter the course of Parkinson's disease in people living with HIV?. 2021 , 27, 595-600	1
232	Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis. 2021 , 1	4
231	Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinson's Disease Population. 2021 , 9,	1
230	Apathy and actions- another consideration when theorizing about embodied nature of language in Parkinson's disease. 2021 , 93, 106144	
229	Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia. 2021 , 4, 1071	3
228	Parkinson's Disease and Eating and Weight Disorders. 2022 , 299-312	
227	Effect of deep brain stimulation on impulse control behaviors of Parkinson's disease patients: A systematic review and meta-analysis. 2021 , 26, 101361	
226	Nonmotor problems in Parkinson disease. 2021 , 234-248.e7	
225	Identification of risk factors for impulse-control disorder symptoms in patients with Parkinson's disease. 2021 , 1722, 012099	
224	Parkinsonism. 2021 , 82-120.e21	
223	Functional correlates of response inhibition in impulse control disorders in Parkinson's disease. 2021 , 32, 102822	0
222	Genetics of Disordered Gambling.	1
221	Substance Use Disorders: Cognitive Sequelae, Behavioral Manifestations, Neuroimaging Correlates, and Novel Interventions. 2019 , 697-728	2

220	Impulse Control Disorders. 2015 , 79-98	1
219	Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats. 2020 , 237, 2419-2431	4
218	Depression and Psychosis in Neurological Practice. 2012 , 92-116	5
217	The Cambridge Handbook of Substance and Behavioral Addictions. 2020 ,	44
216	Beurteilung der Schuldffigkeit bei Glcksspielsucht: Craving als Kriterium einer Einschrnkung der Steuerungsffigkeit. 2019 , 65, 207-215	1
215	CHAPTER 1:Parkinson Disease: Symptoms, Unmet Needs and New Therapeutic Targets. 2013 , 3-25	1
214	Should Hypersexual Disorder be Classified as an Addiction?. 2013 , 20,	49
213	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson disease.	2
212	Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine. 2010 , 2010,	2
211	Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors. 2019 , 129, 3407-3419	47
210	Neuropsychiatric Issues in Parkinson Disease. 2016 , 22, 1086-103	3
209	Clinical Biomarkers of Neurodegeneration in REM Sleep Behavior Disorder. 2015 , 12, 27-33	3
208	Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. 2012 , 7, e29768	83
207	Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa. 2013 , 8, e61197	83
206	MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperprolactinemia treated with dopamine agonists: how much should we worry?. 2018 , 179, R287-R296	13
205	Pharmacological Treatment of Parkinson Disease. 129-144	14
204	[Predictors and modifiers of impulse control disorders in Parkinson's disease]. 2016 , 116, 145-156	3
203	[Syndrome dopamine dysregulation and deep brain stimulation of the subthalamic nucleus in Parkinson's disease]. 2017 , 117, 27-32	2

202	[A clinical and genetic study of impulsive-compulsive disorders in patients with Parkinson's disease]. 2018 , 118, 4-9	2
201	Personality Dimensions in Psychopathy: Potential Explanatory Models for Primary and Secondary Traits.	2
200	Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist. 2016 , 14, 356-63	24
199	Levodopa. 2013 , 389-413	1
198	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale. 2020 , 16, 245-253	3
197	Lack of Association between Impulse Control Disorders and REM Sleep Behavior Disorder in Patients with Parkinson's Disease. 2016 , 05, 67-72	2
196	Decisions, Decisions: The Neurobiology of the effects of Dopamine Replacement Therapy on Decision-Making in Parkinson's Disease. 2015 , 6, 45-52	1
195	Dopaminergic and opioidergic regulation during anticipation and consumption of social and nonsocial rewards. 2020 , 9,	13
194	Orthostatic stability with intravenous levodopa. 2015 , 3, e1198	1
193	Evidence-based pharmacological strategies for gambling disorder. 2021 , 3, 10	
192	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. 2021 , 73, 33-97	2
191	Treatment and Management of Sexual Disinhibition in Elderly Patients With Neurocognitive Disorders. 2021 , 13, e18463	0
190	Interplay Between Inhibitory Control and Behavioural Flexibility: Impact of Dorsomedial Striatal Dopamine Denervation in Mice. 2021 , 477, 25-39	0
189	White matter changes in drug-naïve Parkinson's disease patients with impulse control & probable REM sleep behavior disorders. 2021 , 430, 120032	0
188	Executive function and dopamine response in Parkinson's disease freezing of gait. 2021 , 92, 46-50	1
187	Troubles psychiques et comportementaux de la maladie de Parkinson. 2010 , 194, 1305-1319	
186	Maladie de Parkinson et violences sexuelles. 2011 , 87, 223	
185	Troubles psychiques et comportementaux et leurs traitements. 2011 , 97-109	0

184 Bewegungsstörungen. **2011**, 955-1054

183 Neuropsychiatric Side Effects of Deep Brain Stimulation in Parkinson Disease. **2012**, 159-173

1

182 Parkinson-Therapie heute. **2012**, 33,

181 Assessment. 1-30

180 Dopamine agonists. **2013**, 414-429

179 How May Neuroscience Affect the Way that the Criminal Courts Deal with Addicted Offenders?. **2013**, 279-302

178 Innovative interdisziplinäre Versorgung. **2013**, 24, 16-20

177 Deep Brain Stimulation in Parkinson's Disease: Pallidal (globus pallidus pars interna). 37-43

176 PET and SPECT in Psychiatric Complications of Parkinson Disease. **2014**, 253-269

175 Therapie Psychischer Erkrankungen - Pages 1-91. **2014**, 1-91

174 Impulsivity Imaging. **2014**, 583-620

173 Relationship of Behavioral Addictions to Eating Disorders and Substance Use Disorders. **2014**, 405-428

172 Eine Einführung in Impulskontrollstörungen bei Morbus Parkinson. **2014**, 25, 7-15

171 Addiction aux jeux d'argent : apport des neurosciences et de la neuroimagerie. **2014**, 198, 1309-1325

170 Addictions comportementales dans la maladie de Parkinson. **2014**, 198, 1297-1308

169 [A current view on dopamine receptor agonists in the treatment of Parkinson's disease]. **2015**, 115, 76-83

0

168 Therapie Psychischer Erkrankungen - Pages e1-e96. **2015**, e1-e96

167 Troubles psychiques et comportementaux et leurs traitements. **2015**, 97-111.e3

166 Gambling: Pathological Decision-Making. 1-8

165 Komplexe Verhaltensstörungen unter dopaminergem Therapie. **2016**, 73-79

164 Striatal Mechanisms of Associative Learning and Dysfunction in Neurological Disease. **2016**, 261-287

163 Psychologische aspecten van DBS. **2016**, 61-66

162 Dopaminergic drugs decrease loss aversion in Parkinson disease with but not without depression. 1

161 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. **2017**, 1-111

160 Impulsive Behaviors: Definition, Prevalence, Neurobiology, and Management. **2017**, 215-227 1

159 Combining Multitask Learning and Short Time Series Analysis in Parkinson Disease Patients Stratification. **2017**, 116-125 1

158 Impulse Control Behavior in Movement Disorders: Focus on Restless Leg Syndrome. **2017**, 229-244

157 The Non-motor Parkinson Disease. **2017**, 117-127

156 Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital. **2017**, 06, 101-112

155 Future Directions in Sexual Medicine. **2017**, 583-597

154 Frontotemporal Dementia: A Clue to the Biological Basis of Hubris Syndrome?. **2018**, 3-23

153 Male Sexual Disorders in Patients with Parkinson Disease: Treatment with Natural Remedies. **2017**, 3, 1

152 Idiopathisches Parkinson-Syndrom (IPS). **2018**, 1-32

151 Gambling Disorder in the Context of Parkinson Disease. **2018**, 5,

150 Agitation et troubles du contrôle des impulsions. **2018**, 350-359

149 Subjective estimates of uncertainty during gambling and impulsivity after subthalamic deep brain stimulation for Parkinson disease.

- 148 Abnormal Subcortical Volumes and Cortical Thickness in Parkinson's Disease with Impulse Control Disorders. **2019**, 22, 426-431 1
- 147 Psychiatric Symptoms Comorbid with Neurological Syndromes. **2019**, 201-218
- 146 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119
- 145 Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner.
- 144 Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs. **2020**, 1-10
- 143 Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes. **2020**, 1-29
- 142 Impulse Control Disorders in Parkinson's disease.
- 141 Hypersexuality Due to Adverse Effects of Medicines and Surgical Interventions. **2020**, 57-63
- 140 Intimacy, parkinson's disease and dementia in the time of the coronavirus. **2020**, 029-030
- 139 Clinical Topics in Old Age Psychiatry. **2020**,
- 138 Preface. **2020**, xv-xvii
- 137 Nigral and ventral tegmental area lesioning induces testicular and sperm morphological abnormalities in a rotenone model of Parkinson's disease. **2020**, 78, 103412 1
- 136 Effects of dopamine agonist treatment on resting-state network connectivity in Parkinson's disease.
- 135 Clinical and pathophysiological aspects of non-motor manifestations of Parkinson's disease. **2020**, 18, 222-232
- 134 PET and SPECT in Psychiatric Complications of Parkinson's Disease. **2021**, 297-315
- 133 Impulsivity Imaging. **2021**, 773-816
- 132 Integrating Neurology and Psychiatry throughout Educational Curricula for Healthcare Professionals. **2020**, 1, 168-172
- 131 Dopamine genetic risk score predicts impulse control behaviors in Parkinson's disease. **2021**, 5, 100113 0

130 Adult ADHD in Neurocognitive and Neurological Disorders. **2020**, 287-305

129 Idiopathisches Parkinson-Syndrom (IPS). **2020**, 1293-1324

128 Ethical and Legal Issues in Deep Brain Stimulation: An Overview. **2020**, 319-337

127 Adult ADHD and Non-Substance-Related Disorders. **2020**, 271-286

126 Impulse Control and Related Disorders in Parkinson's Disease: Special Issues and Implications. **2020**, 50, 107-112

125 Dopaminergic Co-transmission with Sonic Hedgehog Inhibits Abnormal Involuntary Movements.

124 Troubles du contrôle des impulsions dans la maladie de Parkinson : spectre clinique, physiopathologie et prise en charge. **2020**, 11, 129-134

0

123 A Behavioral Association Between Prediction Errors and Risk-Seeking: Theory and Evidence.

122 D-Like Receptor Expression in the Hippocampus and Amygdala Informs Performance on the Stop-Signal Task in Parkinson's Disease. **2021**, 41, 10023-10030

1

121 Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease. **2021**, 12, 733570

120 Update on the diagnosis and management of Parkinson's disease. **2020**, 20, 393-398

7

119 Positron emission tomography neuroimaging in Parkinson's disease. **2011**, 3, 323-41

44

118 New perspectives in the care of Parkinson disease. **2012**, 109, 328-32

1

117 Gender Differences in Impulse Control Disorders and Related Behaviors in Patients with Parkinson's Disease and its Impact on Quality of Life. **2020**, 23, 632-637

116 Neurobiology and Genetics of Behavioral Addictions: A Brief Review. **2022**, 23, 1-1

115 The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. **2021**,

114 Parkinson's disease and Behavioural Addiction: The susceptibilities and risks.. **2021**, 68, 102960

113 [Hallucinations in Patients with Idiopathic Parkinson's Disease]. **2021**,

0

112 Dopamine devils. **2021**, 79, 941-942

111 Assessment of therapeutic strategies for management of impulse control disorder in Parkinson's disease. **2021**, 79, 989-994

110 Cognitive and Behavior Deficits in Parkinson's Disease with Alteration of FDG-PET Irrespective of Age. **2021**, 6,

109 Reply to 'Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.'. **2021**, 93, 31-32

108 [Speech and behavioral contaminations as non-epileptic automatic behavior in Parkinson's disease]. **2021**, 121, 58-63

107 The neuropsychiatry of Parkinson's disease: advances and challenges.. **2022**, 21, 89-102

106 Morbus Parkinson: Ist mein Patient noch fahrt chtig?.

105 Cas 5. Addictions comportementales et apathie dans la maladie de Parkinson : d n extr me ^ l butre. **2018**, 113-152

104 Impact de la stimulation c brale profonde sur les troubles du contr le des impulsions dans la maladie de Parkinson. **2022**,

103 Diagnostic work up: Laboratory and biomarkers.. **2022**, 162, 53-96

102 Prevalence, clinical presentations and impact on relationship.. **2022**, 162, 1-19

101 Dopamine Agonist-Induced Impulse Control Disorders. **2022**, 43-53

100 A circuit-based approach to repair hypersexuality in Parkinson's disease.

99 Compulsive Sexual Behavior. **2022**, 69-91

98 Exploring sexual dysfunction in care homes.. **2022**, 162, 135-170

97 Management strategies of sexual dysfunctions in Parkinson's disease.. **2022**, 162, 97-116

96 The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting.. **2022**, 181, 157-157

95 Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29).. **2022**, 2698811211969102

94	Neural correlates of impaired response inhibition in the antisaccade task in Parkinson's disease.. 2022 , 422, 113763	
93	The epidemiology of cognitive function in Parkinson's disease.. 2022 , 269, 3-37	0
92	Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease.. 2022 , 269, 309-343	0
91	Cognitive dysfunction and neuropsychiatric aspects of Parkinson's disease.. 2022 , 269, 59-90	0
90	Decision making under uncertainty in Parkinson's disease with Rem sleep behavior disorder.. 2022 , 90, 214-221	1
89	Psychiatric symptoms of frontotemporal dementia and subcortical (co-)pathology burden: new insights.. 2022 ,	0
88	White matter microstructures in Parkinson's disease with and without impulse control behaviors.. 2022 ,	1
87	Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson's disease. 2021 , 7, 112	1
86	Bibliographie. 2021 , 399-409	
85	Impulse control disorders, dopamine dysregulation syndrome and sex dysfunction in Parkinson's disease.. 2022 , 162, 117-134	
84	Prologue: Why should we talk about sex and Parkinson's disease?. 2022 , 162, xi-xiv	
83	The impact of nonmotor symptom burden on sexual function.. 2022 , 162, 185-201	
82	Trait Anxiety as a Risk Factor for Impulse Control Disorders in de novo Parkinson's Disease.. 2021 ,	0
81	Impulse Control Disorders and the Dopamine Dysregulation Syndrome. 2022 , 224-240	
80	Sexual Dysfunction in Parkinson's Disease. 2022 , 155-166	
79	Validation of the Japanese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).. 2022 , 2022, 1503167	1
78	A single-arm open-label pilot study of brief mindfulness meditation to control impulsivity in Parkinson's disease.. 2022 , 17, e0266354	
77	Gambling disorder in the UK: key research priorities and the urgent need for independent research funding.. 2022 , 9, 321-329	5

- 76 Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase.. **2022**, 58, 30-38 ○
- 75 Fahrtauglichkeit bei Parkinson-Erkrankung. **2021**, 04, 325-339
- 74 The Reward Deficiency Syndrome and Links with Addictive and Related Behaviors. **2022**, 1-16 ○
- 73 Drug Treatment of Psychiatric Symptoms Occurring in the Context of Other Disorders. 777-830 ○
- 72 Genetic Markers as Risk Factors for the Development of Impulsive-Compulsive Behaviors in Patients with Parkinson's Disease Receiving Dopaminergic Therapy.. **2021**, 11, ○
- 71 Validation of the Chinese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease.. **2021**, 12, 731552
- 70 Amphetamine-induced dopamine release and impulsivity in Parkinson disease.. **2021**,
- 69 The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study.. **2022**, 22, 97 ○
- 68 Forward and backward spatial recall in Parkinson's disease and matched controls: A 1-year follow-up study.. **2022**, 1-10
- 67 Data_Sheet_1.docx. **2018**,
- 66 Image_1.jpeg. **2018**,
- 65 Image_2.jpeg. **2018**,
- 64 Table_1.PDF. **2018**,
- 63 table_1.docx. **2018**,
- 62 Table_1.DOCX. **2020**,
- 61 Table_2.DOCX. **2020**,
- 60 Table_3.DOCX. **2020**,
- 59 Table_4.DOCX. **2020**,

58 Table_1.DOCX. **2019,**

57 Table_2.docx. **2019,**

56 Table_3.docx. **2019,**

55 Table_1.DOCX. **2018,**

54 Table_2.DOCX. **2018,**

53 Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.. **2022,** 2

52 Machine learning-based prediction of impulse control disorders in Parkinson's disease from clinical and genetic data. **2022,** 1-1

51 Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment through the FDA Adverse Event Reporting System. 1

50 High- and Low-Frequency Deep Brain Stimulation in the Subthalamic Nucleus differentially modulate Response Inhibition and Action Selection in Parkinson's Disease.

49 Spiritual care for the management of Parkinson's disease: Where we are and how far can we go. 0

48 New-onset impulse control disorders after treatment with levodopa/parbidopa intestinal gel in Parkinson's disease. **2022,** 0

47 Deep brain stimulation rectifies the noisy cortex and irresponsive subthalamus to improve parkinsonian locomotor activities. **2022,** 8, 0

46 A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living. 0

45 Inhibitory framing in hypersexual patients with Parkinson's disease. An fMRI pilot study. **2022,** 240, 2097-2107 0

44 Genetic prediction of impulse control disorders in Parkinson's disease. **2022,** 9, 936-949 0

43 Neural correlates of risky decision making in Parkinson's disease patients with impulse control disorders. 0

42 Movement Disorders. **2022,** 218-234

41 Update on Gambling Disorder. **2022,** 0

- 40 Clinical trajectories and biomarkers for weight variability in early Parkinson disease. **2022**, 8, ○
- 39 Motivational disturbances in rodent models of neuropsychiatric disorders. 16, ○
- 38 Subjective Feelings associated with Expectations and Rewards during Risky Decision-making in Impulse Control Disorder. ○
- 37 REM Sleep Behaviour Disorder in Parkinson disease: A survey based study. 1-21 ○
- 36 Premorbid performances determine the deleterious effects of nigrostriatal degeneration and pramipexole on behavioural flexibility. ○
- 35 Parkinson Disease. **2022**, 169-181 ○
- 34 Sex Addiction. **2022**, 161-188 ○
- 33 Cognitive Behavioral Therapy Plus a Serious Game as a Complementary Tool for a Patient With Parkinson Disease and Impulse Control Disorder: Case Report. **2022**, 10, e33858 ○
- 32 Do Impulse Control Disorders Impair Car Driving Performance in Patients with Parkinson Disease?. **2022**, 1-15 ○
- 31 Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. ○
- 30 Early hyperdopaminergic state following sub-thalamic nucleus deep brain stimulation in Parkinson disease. **2022**, ○
- 29 The Reward Deficiency Syndrome and Links with Addictive and Related Behaviors. **2022**, 59-74 ○
- 28 Jogo patológico versus transtorno de jogo: o estado de arte. **2022**, 15, 36-57 ○
- 27 Management of psychiatric and cognitive complications in Parkinson disease. e068718 ○
- 26 Parkinson disease impairs cortical sensori-motor decision-making cascades. ○
- 25 Performance on the Balloon Analogue Risk Task and Anticipatory Response Inhibition Task is Associated with Severity of Impulse Control Behaviours in People with Parkinson Disease. ○
- 24 Computational reinforcement learning, reward (and punishment), and dopamine in psychiatric disorders. 13, ○
- 23 Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes. **2022**, 2917-2945 ○

22	Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs. 2022 , 2963-2972	0
21	The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder. 2022 , 24, 10-69	2
20	Should patients with Parkinson's disease only visit a neurologist's office? - a narrative review of neuropsychiatric disorders among people with Parkinson's disease. 2022 ,	0
19	Primary neurology healthcare and prescription drug addiction. 2022 , 23, 463-467	0
18	Dopamine agonist monotherapy utilization in patients with Parkinson's disease. 2022 , 100173	0
17	Dissociable behavioural signatures of co-existing impulsivity and apathy in decision-making. 2022 , 12,	0
16	Quality of life implications for elevated trait impulsivity in people with Parkinson's disease.	0
15	Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management.	0
14	High (130 Hz)- and mid (60 Hz)-frequency deep brain stimulation in the subthalamic nucleus differentially modulate response inhibition: A preliminary combined EEG and eye tracking study. 2023 , 37, 103314	0
13	D2/3Agonist during Learning Potentiates Cued Risky Choice. JN-RM-1459-22	0
12	Deep brain stimulation and dopamine medication enhance free choice preference in Parkinson's disease.	0
11	Anatomical Patterns Recognition of Impulse Control Disorders of Parkinsonian Patients Using Deep Learning of MRI structural images. 2022 ,	0
10	Prevalence and Possible Predictors of Gambling Disorder in a Sample of Students in the Healthcare Professions. 2023 , 20, 452	0
9	A circuit-based approach to modulate hypersexuality in Parkinson's disease.	0
8	Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease. 16,	0
7	Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study. 2023 , 130, 125-133	0
6	The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine. 2023 , 245, 108392	0
5	Pramipexole restores behavioral inhibition in highly impulsive rats through a paradoxical modulation of frontostriatal networks.	0

- 4 Creativity and Parkinson's Disease. **2023**, 65-89 ○
- 3 Premorbid performances determine the deleterious effects of nigrostriatal degeneration and pramipexole on behavioural flexibility. **2023**, 9, ○
- 2 Performance on the balloon analogue risk task and anticipatory response inhibition task is associated with severity of impulse control behaviours in people with Parkinson's disease. **2023**, 241, 1159-1172 ○
- 1 New-onset impulse control disorders after treatment with levodopa-carbidopa intestinal gel in Parkinson's disease. **2023**, 38, 220-221 ○